Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Hold” from Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) has received a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $111.93.

A number of analysts have recently issued reports on the stock. Jefferies Financial Group cut shares of Neurocrine Biosciences to a “hold” rating and set a $94.00 target price for the company. in a research note on Thursday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price target on shares of Neurocrine Biosciences in a research report on Monday, February 14th. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Wedbush reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Thursday, April 28th. Finally, Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday, February 14th.

In other news, Director William H. Rastetter sold 10,728 shares of Neurocrine Biosciences stock in a transaction on Friday, April 1st. The shares were sold at an average price of $94.93, for a total value of $1,018,409.04. Following the completion of the sale, the director now owns 34,022 shares in the company, valued at approximately $3,229,708.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Darin Lippoldt sold 300 shares of Neurocrine Biosciences stock in a transaction on Friday, March 18th. The shares were sold at an average price of $95.00, for a total transaction of $28,500.00. The disclosure for this sale can be found here. Insiders sold a total of 49,483 shares of company stock worth $4,386,457 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in NBIX. Whittier Trust Co. increased its stake in Neurocrine Biosciences by 102.8% during the 4th quarter. Whittier Trust Co. now owns 290 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares in the last quarter. IndexIQ Advisors LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth $27,000. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth $27,000. Moors & Cabot Inc. bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth $30,000. Finally, KB Financial Partners LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $33,000. Institutional investors and hedge funds own 93.21% of the company’s stock.

Shares of NBIX stock opened at $84.12 on Monday. The stock has a market cap of $8.04 billion, a P/E ratio of 116.83 and a beta of 0.70. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.02 and a quick ratio of 3.90. The company has a fifty day moving average price of $92.32 and a two-hundred day moving average price of $87.16. Neurocrine Biosciences has a one year low of $71.88 and a one year high of $108.01.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The firm had revenue of $310.60 million during the quarter, compared to analyst estimates of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a return on equity of 5.30%. The business’s revenue was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 1.91 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.